TG Therapeutics – Trademark Portfolio
Entity Type: 03
TG Therapeutics holds 12 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 11 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include UKONIQ and TG PATIENTSUPPORT. The owner is based in New York, NY.
2 Gansevoort Street, 9th Floor
New York, NY 10014
Showing of trademarks Trademarks
Trademark Classifications
TG Therapeutics's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Insurance; financial affairs; monetary affairs; real estate affairs
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does TG Therapeutics have?
TG Therapeutics has 12 U.S. trademarks filed with the USPTO. Of these, 2 registered, 10 abandoned.
What trademark classes does TG Therapeutics file in?
TG Therapeutics files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 36 (Insurance & Financial), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are TG Therapeutics's most well-known trademarks?
TG Therapeutics's registered trademark portfolio includes well-known marks such as UKONIQ and TG PATIENTSUPPORT. These are among 2 currently registered trademarks in the portfolio.
What is TG Therapeutics's trademark registration success rate?
TG Therapeutics has a 17% trademark registration rate, with 2 out of 12 resolved applications resulting in successful registration. Currently, 0 applications are pending review.